Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative colitis (UC). A range of 5-ASA preparations is available and Eudragit-S® coated modified release formulations of mesalamine, such as Asacol®, remain among the most popular choices. We here review the current und...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2009
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108647/ |